Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
A summer wave of cases locally and across the country may be on the decline and a vaccine targeting the latest variants is ...
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...
It’s been over four years since the beginning of the COVID-19 pandemic. And since then, the virus has changed substantially.
Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...
Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
Flu season approaches and there's a new COVID variant. The time to act is now, or soon, according to the two largest local ...